BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11146451)

  • 1. Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat.
    Norrby K; Mattsby-Baltzer I; Innocenti M; Tuneberg S
    Int J Cancer; 2001 Jan; 91(2):236-40. PubMed ID: 11146451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human apo-lactoferrin enhances angiogenesis mediated by vascular endothelial growth factor A in vivo.
    Norrby K
    J Vasc Res; 2004; 41(4):293-304. PubMed ID: 15192265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.
    Bauer KS; Cude KJ; Dixon SC; Kruger EA; Figg WD
    J Pharmacol Exp Ther; 2000 Jan; 292(1):31-7. PubMed ID: 10604929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
    Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
    Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
    Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
    Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.
    Hernández GL; Volpert OV; Iñiguez MA; Lorenzo E; Martínez-Martínez S; Grau R; Fresno M; Redondo JM
    J Exp Med; 2001 Mar; 193(5):607-20. PubMed ID: 11238591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo.
    Mantell DJ; Owens PE; Bundred NJ; Mawer EB; Canfield AE
    Circ Res; 2000 Aug; 87(3):214-20. PubMed ID: 10926872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bovine lactoferrin inhibits tumor-induced angiogenesis.
    Shimamura M; Yamamoto Y; Ashino H; Oikawa T; Hazato T; Tsuda H; Iigo M
    Int J Cancer; 2004 Aug; 111(1):111-6. PubMed ID: 15185351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
    Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tecogalan sodium on angiogenesis in vitro by choroidal endothelial cells.
    Sakamoto T; Ishibashi T; Kimura H; Yoshikawa H; Spee C; Harris MS; Hinton DR; Ryan SJ
    Invest Ophthalmol Vis Sci; 1995 May; 36(6):1076-83. PubMed ID: 7537258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo.
    McNamara DA; Harmey J; Wang JH; Kay E; Walsh TN; Bouchier-Hayes DJ
    Eur J Surg Oncol; 2001 Dec; 27(8):714-8. PubMed ID: 11735166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
    Roman CD; Choy H; Nanney L; Riordan C; Parman K; Johnson D; Beauchamp RD
    J Surg Res; 2002 Jun; 105(1):43-7. PubMed ID: 12069500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
    Hirata A; Ogawa S; Kometani T; Kuwano T; Naito S; Kuwano M; Ono M
    Cancer Res; 2002 May; 62(9):2554-60. PubMed ID: 11980649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action.
    Waltenberger J; Mayr U; Frank H; Hombach V
    J Mol Cell Cardiol; 1996 Jul; 28(7):1523-9. PubMed ID: 8841939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.
    Binétruy-Tournaire R; Demangel C; Malavaud B; Vassy R; Rouyre S; Kraemer M; Plouët J; Derbin C; Perret G; Mazié JC
    EMBO J; 2000 Apr; 19(7):1525-33. PubMed ID: 10747021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.